

COST SAVINGS ASSOCIATED WITH EMICIZUMAB REPACKAGING IN PEDIATRIC PATIENTS WITH HEMOPHILIA A

Saldaña Soria Raquel, Florit Sánchez María, Yunquera Romero Lucía, Fernández Martín Jesús, Gallego Fernández Carmen, Tortajada Goitia Begoña
Hospital Materno-Infantil de Málaga. Málaga. Spain




What was done?

Emicizumab is indicated for hemophilia A. This drug has a significant economic impact, so a protocol was implemented to optimize the use of emicizumab by grouping patients and dispensing pre-filled syringes of repackaged emicizumab, adjusting doses per patient.

Why was it done?

The aim was to evaluate and quantify the cost savings resulting from the optimization of emicizumab vial.



How was it done?

February 2022 - September 2024
Two male pediatric patients with hemophilia A were treated with emicizumab in our hospital.

The protocol involved

- Grouping patients to dispense repackaged, pre-filled syringes of emicizumab on the same day.
- Dividing each vial according to the patient's dose, based on the recommended dose in the Technical Data Sheet.
- All repackaging was done under aseptic conditions in a laminar flow cabinet.

What has been achieved?

- **Total cost without optimization:** 337,125.95€
- **Total cost with optimization:** 168,562.98€
- **Cost savings:** 168,562.98€ (63,211.12€/year)

This method contributes to the **sustainability of the national healthcare system.**



What is next?

- Expand the protocol to include all pediatric patients at our hospital.
- Continue monitoring cost efficiency and patient outcomes.

PC50108

